A common criticism of tech stocks is that too many of them are "priced for perfection", but even more puzzling to us are those tech companies that appear to be priced for imperfection, such as this one. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
A common criticism of tech stocks is that too many of them are "priced for perfection", but even more puzzling to us are those tech companies that appear to be priced for imperfection, such as this one. Read More
As described in today’s edition of Smart Tech 50 Weekly Movers, we are adding Neurocrine Biosciences (NSDQ: NBIX) to the STI Equity Trades Portfolio with a buy limit of $46, and a stop loss of $36. Read More
As described in today’s edition of Smart Tech 50 Weekly Movers, we are adding Neurocrine Biosciences (NSDQ: NBIX) to the STI Equity Trades Portfolio with a buy limit of $46, and a stop loss of $36. Read More
It’s hard to believe that the biotech sector, known for its inherent volatility, is an island of relative stability in an increasingly volatile stock market. Read More
It’s hard to believe that the biotech sector, known for its inherent volatility, is an island of relative stability in an increasingly volatile stock market. Read More
Now that the Memorial Day weekend is in our rear view mirror, it is fair to ask if the old stock market adage, “Sell in May and then go away” will turn out to be good advice for tech stocks this year. They certainly have had a very nice run… Read More
Now that the Memorial Day weekend is in our rear view mirror, it is fair to ask if the old stock market adage, “Sell in May and then go away” will turn out to be good advice for tech stocks this year. They certainly have had a very nice run… Read More
A confluence of macro factors are driving up home sales. Read More
- May 18, 2015
-
Download Issue
Recently we added Dr. Joe Duarte to our research team at Smart Tech Investor, and have been very impressed with his insight and analysis. Although we realize the biotech sector has appreciated considerably during the past year and may be due for a correction, we feel the long term upside… Read More